Nisa Investment Advisors’s NextCure NXTC Stock Holding History

Nisa Investment Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-175	Closed	-$21	–	2367
2021 Q1	$21	Hold	175	–	–	﹤0.01%	2123
2020 Q4	$23K	Buy	+175	New	+$22.6K	﹤0.01%	2100

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nisa Investment Advisors's NXTC Position: Q2 2021 in Review

Nisa Investment Advisors sold out of NextCure (NXTC) in Q2 2021, closing a stake of 175 shares — an estimated $21 sold.

Nisa Investment Advisors first reported a position in NXTC in Q4 2020 and held it in 2 quarters. The position peaked at $23K in Q4 2020. 78 funds tracked by Wall St. Rank hold NXTC as of Q2 2021.

Nisa Investment Advisors reported no remaining NextCure position as of Q2 2021 after selling out during the quarter.
Nisa Investment Advisors sold 175 NextCure shares in Q2 2021, an estimated $21.
Nisa Investment Advisors first reported a position in NextCure in Q4 2020 and held it in 2 quarters.
Nisa Investment Advisors's NextCure position peaked at $23K in Q4 2020.
78 funds tracked by Wall St. Rank held NextCure as of Q2 2021.

Based on Nisa Investment Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.